Here's the latest variant picture for Northern Ireland, to late February.

BA.3.2.* "Cicada" has been dominant at 67%.

XFG.* "Stratus" continued falling to finish at 39%

No samples have been shared from the other home countries since February 9.

#COVID19 #SARSCoV2 #UK #BA_3_2 #Cicada

Here's the latest variant picture for the United Kingdom, to mid-February.

BA.3.2.* "Cicada" continued to dominate at 72%.

XFG.* "Stratus" continued falling to finish at 25%

Recent samples are only from Northern Ireland.

#COVID19 #SARSCoV2 #UK #BA_3_2 #Cicada
🧵

Here's the latest variant picture for the United Kingdom, to early February.

BA.3.2.* "Cicada" continued its sharp grew suddenly and took over dominance at 44%.

XFG.* "Stratus" continued falling to finish at 32%

#COVID19 #SARSCoV2 #UK #BA_3_2 #Cicada
🧵

Here's the latest variant picture for the United Kingdom, to late January.

XFG.* "Stratus" continued falling sharply to finish at 38%

BA.3.2.* grew suddenly and is challenging for dominance at 34%.

#COVID19 #SARSCoV2 #UK #BA_3_2 #Cicada
🧵

Here's the latest variant picture for the United Kingdom, to mid-January.

XFG.* "Stratus" remained dominant, but fell sharply to 44%

NB.1.8.1.* "Nimbus" grew steadily to 31%.

BA.3.2.* fell slightly to 20%.

#COVID19 #SARSCoV2 #UK #BA_3_2 #Cicada
🧵

Here's the latest variant picture for Europe (excluding the UK), to early January.

BA.3.2.* "Cicada" showed a steady growth advantage of 7% per day (49% per week) over XFG.* "Stratus", with a crossover in late December.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for the United Kingdom, to early January.

BA.3.2.* soared to 70% of recent samples in Scotland.

#COVID19 #SARSCoV2 #UK #BA_3_2 #Cicada
🧵

Here's the latest variant picture for Australia, to early January.

The overall view is muddied by patchy sequencing volumes. BA.3.2.* "Cicada", NB.1.8.1.* "Nimbus", JN.1.* +DeFLuQE (led by PE.1.4) and XFG.* "Stratus" all finished in the 22-26% range.

#COVID19 #SARSCoV2 #Australia #BA_3_2
🧵

Here's the latest variant picture with a global scope, to early January.

Globally from November, BA.3.2.* "Cicada" showed a growth advantage of 3.5% per day (25% per week) over XFG.* "Stratus".

#COVID19 #SARSCoV2 #Global #BA_3_2 #Cicada
🧵

Here's the latest variant picture for Australia, to late December.

The overall view is muddied by patchy sequencing volumes. BA.3.2.* finished at 27% with NB.1.8.1.* "Nimbus" just higher at 35%.

#COVID19 #SARSCoV2 #Australia #BA_3_2
🧵

Here's the latest variant picture with a global scope, to late December.

BA.3.2.* "Cicada" showed a growth advantage of 5% per day (35% per week) over XFG.* "Stratus". The low sample sizes for late-December make this even more uncertain than usual.

#COVID19 #SARSCoV2 #Global #BA_3_2 #Cicada
🧵

Here's the latest variant picture for Europe (excluding the UK), to the end of November.

BA.3.2.* "Cicada" showed a slightly slowing growth advantage of 7% per day (49% per week) over XFG.* "Stratus", which predicts a crossover in late December.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for the United Kingdom, to the end of November.

For the UK, BA.3.2.* "Cicada" showed a slowing growth advantage of 3.2% per day (22% per week) over XFG.* "Stratus", which predicts a crossover in late January.

#COVID19 #SARSCoV2 #UK #BA_3_2 #Cicada
🧵

Here's the latest variant picture for South Australia, to late November.

NB.1.8.1.* "Nimbus" is dominant but generally falling, finishing at 56%. JN.1.* +DeFLuQE (led by PE.1.4) is also very significant at 37%.

No further samples of BA.3.2.* were reported.

#COVID19 #SARSCoV2 #Australia #BA_3_2
🧵

Here's the latest variant picture with a global scope, to late November.

Globally from October, BA.3.2.* "Cicada" showed a growth advantage of 4.7% per day (33% per week) over XFG.* "Stratus". This has been skewed down by a massive dump from Canada.

#COVID19 #SARSCoV2 #Global #BA_3_2 #Cicada
🧵

Here's the latest variant picture for Europe (excluding the UK), to late November.

BA.3.2.* "Cicada" is showing a very strong growth advantage of 7.9% per day (55% per week) over XFG.* "Stratus", which predicts a crossover in late December.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for the United Kingdom, to late November.

For the UK, BA.3.2.* "Cicada" is showing a strong growth advantage of 5% per day (35% per week) over XFG.* "Stratus", which predicts an imminent crossover.

#COVID19 #SARSCoV2 #UK #BA_3_2 #Cicada
🧵

Here's the latest variant picture for Australia, to late November.

For Australia, BA.3.2.* "Cicada" is showing a steady growth advantage of 2.5% per day (18% per week) over NB.1.8.1.* "Nimbus", which predicts an imminent crossover (the data routinely lags).

#COVID19 #SARSCoV2 #Australia #BA_3_2
🧵

Here's the latest variant picture with a global scope, to late November.

Globally from October, BA.3.2.* "Cicada" showed a strong growth advantage of 5.5% per day (39% per week) over XFG.* "Stratus". A crossover looks likely during January at that pace.

#COVID19 #SARSCoV2 #Global #BA_3_2 #Cicada
🧵

Here's the latest variant picture for Europe (excluding the UK), to mid-November.

BA.3.2.* "Cicada" is showing continued signs of growth. Recent samples have been reported from Germany and Ireland.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for South Australia, to late November.

NB.1.8.1.* "Nimbus" is dominant, finishing at 65%. JN.1.* +DeFLuQE (led by PE.1.4) is also significant at 26%.

The first sample of BA.3.2.* was reported.

#COVID19 #SARSCoV2 #Australia #BA_3_2
🧵

Here's the latest variant picture with a global scope, to mid-November.

BA.3.2.* has continued to show signs of growth. Recent samples have been reported from South Africa, Australia, across Europe, and a traveller entering the US from Kenya.

#COVID19 #SARSCoV2 #Global #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for Europe (excluding the UK), to early November.

BA.3.* (mostly BA.3.2.2) is showing continued signs of growth. Recent samples have been reported from Ireland.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for Australia, to early November.

BA.3.* (all BA.3.2.2) rose to 13% and seems the most likely challenger to replace NB.1.8.1.* "Nimbus".

#COVID19 #SARSCoV2 #Australia #BA_3_2
🧵

Here's the latest variant picture with a global scope, to early November.

BA.3.* (mostly BA.3.2.2) has continued to show signs of growth. Recent samples have been reported from South Africa, Australia and across Europe.

#COVID19 #SARSCoV2 #Global #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for Europe (excluding the UK), to early November.

BA.3.* (mostly BA.3.2.2) has started showing significant signs of growth. Recent samples have mostly been reported from Germany and the Netherlands.

#COVID19 #SARSCoV2 #EUR #BA_3_2 #XFG #Stratus
🧵

Here's the latest variant picture for Australia, to early November.

BA.3.* (all BA.3.2.2) rose to 19% and seems the most likely challenger to replace NB.1.8.1.* "Nimbus".

#COVID19 #SARSCoV2 #Australia #BA_3_2
🧵

Here's the latest variant picture with a global scope, to early November.

BA.3.* (mostly BA.3.2.2) has started showing significant signs of growth. Recent samples have mostly been reported from Germany and Australia.

#COVID19 #SARSCoV2 #Global #BA_3_2 #XFG #Stratus
🧵

I’ve used WA Health’s COVID-19 wastewater surveillance page to estimate the number of infections of BA.3.2.

I estimate ~300 BA.3.2.* infections in Perth for the latest week, and ~6,000 across the 12 weeks since BA.3.2.* was first detected.

#COVID19 #SARSCoV2 #BA_3_2 #Australia #WA #Perth
🧵

I’ve used WA Health’s COVID-19 wastewater surveillance page to estimate the number of infections of BA.3.2.

I estimate ~1,100 BA.3.2.* infections in Perth for the latest week, and ~5,700 over the 11 weeks since BA.3.2.* was first detected.

#COVID19 #SARSCoV2 #BA_3_2 #Australia #WA #Perth
🧵